Company Description
BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology.
The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.
It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions.
The company has collaboration agreement with MSD for the cancer immunotherapy field; and MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer, as well as licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010.
BioLineRx Ltd. was incorporated in 2003 and is headquartered in Modi'in, Israel.
| Country | Israel |
| Founded | 2003 |
| IPO Date | Jul 25, 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 79 |
| CEO | Philip A. Serlin CPA, M.B.A., CPA, MBA |
Contact Details
Address: 2 Hama-ayan Street, Modi-in Technology Park Modi-in, L3 7177871 Israel | |
| Phone | 972-2-548-9100 |
| Website | biolinerx.com |
Stock Details
| Ticker Symbol | BLRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001498403 |
| CUSIP Number | 09071M205 |
| ISIN Number | US09071M2052 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Philip A. Serlin CPA, M.B.A., CPA, MBA | Chief Executive Officer |
| Mali Zeevi CPA, CPA | Chief Financial Officer |
| Dr. Ella Sorani Ph.D. | Chief Development Officer |
| Holly W. May M.B.A. | President of BioLineRx USA |
| John Lacey | Head of Corporate Communications and Investor Relations |
| Tsipi Keren-Lehrer B.Sc., L.L.B. | Head of BD and Strategic Advisor |
| Raziel Fried | Treasurer and Budgetary Control Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2024 | 6-K | Report of foreign issuer |
| Apr 10, 2024 | 6-K | Report of foreign issuer |
| Apr 1, 2024 | 6-K | Report of foreign issuer |
| Apr 1, 2024 | 424B5 | Filing |
| Mar 26, 2024 | 20-F/A | Filing |
| Mar 26, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Mar 26, 2024 | 6-K | Report of foreign issuer |
| Mar 4, 2024 | 6-K | Report of foreign issuer |
| Feb 28, 2024 | 6-K | Report of foreign issuer |
| Feb 16, 2024 | 6-K | Report of foreign issuer |